Why I might buy this soaring stock alongside the Glaxo (GSK) share price

I say GlaxoSmithKline (LON: GSK) is a great investment, but why is this blue-sky biotech making the headlines right now?

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Biotechnology hopefuls come into and go out of fashion from time to time, and the one hitting the headlines at the moment is PureTech Health (LSE: PRTC).

PureTech shares climbed 20% at one point Tuesday, after the share price of Karuna Therapeutics multiplied more than five-fold overnight on the back of a positive clinal trial result. Karuna’s KarXT treatment for schizophrenia is in phase II trials and has reported above-average results, and that’s expected to help clear the way for regulatory approval.

PureTech shares responded with their own gain because the company owns 31.6% of Karuna. PureTech’s holding in Karuna is now worth around $580m, up from $130m last week. To me, it doesn’t look as if the PureTech rise fully incorporates the jump in Karuna’s valuation.

Not to be missed?

Analysts appear to agree, and have been wasting no time in reaffirming their buy ratings on the stock – with Liberum Capital and Peel Hunt among those getting in on the bullish optimism.

According to the perfect markets theory, it’s impossible to get ahead of the market because all new information is instantly available to all players and is immediately factored into share prices. In the wider sense, the theory ignores all sorts of factors that drive share prices, but in this case there could well be a short-term anomaly that hasn’t worked its way through yet.

In the short term, we’ll have to see what happens to the PureTech share price over the next few days, but looking at the bigger picture it seems possible that this could be the breakthrough that puts PureTech on the road to profit – current forecasts for further losses make it otherwise very difficult to value.

Safe cash

If I ever did invest in a blue-sky biotech prospect, it would only be a small amount of cash and it would be alongside a bigger investment in an established pharmaceuticals company like GlaxoSmithKline (LSE: GSK) – to sort of balance the overall risk of investing in the medical field.

Glaxo, in fact, is one of those perpetual Buy stocks that I’ve always seen as a great long-term investment, but I’ve never actually got round to picking up any shares.

Over the past five years I’ve missed a fairly modest 24% gain as the company has really only just started back on the road to earnings growth after having to invest heavily to rebuild its drug development pipeline. But that’s still around twice the performance of the FTSE 100, and Glaxo has been paying annual dividends yielding more than 5% for the period.

Still cheap?

Though the share price has appreciated strongly over the past two years, I still reckon we’re looking at very good value with forward price-to-earnings multiples of around 14 being pretty much bang on the Footsie’s long-term average.

Under the leadership of current chief executive Emma Walmsley, the company is well on its way to transforming itself with a long-term plan to separate its pharmaceuticals and consumer businesses, and I think that’s a sound way forward.

To be fair, there’s not much to choose between Glaxo and FTSE 100 rival AstraZeneca, but I think either should provide great long-term rewards.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Alan Oscroft has no position in any of the shares mentioned. The Motley Fool UK owns shares of and has recommended GlaxoSmithKline. The Motley Fool UK has recommended AstraZeneca. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

Surely, the Rolls-Royce share price can’t go any higher in 2025?

The Rolls-Royce share price was the best performer on the FTSE 100 in 2023 and so far in 2024. Dr…

Read more »

A young woman sitting on a couch looking at a book in a quiet library space.
Investing Articles

Here’s how an investor could start buying shares with £100 in January

Our writer explains some of the things he thinks investors on a limited budget should consider before they start buying…

Read more »

Investing Articles

Forget FTSE 100 airlines! I think shares in this company offer better value to consider

Stephen Wright thinks value investors looking for shares to buy should include aircraft leasing company Aercap. But is now the…

Read more »

Investing Articles

Are Rolls-Royce shares undervalued heading into 2025?

As the new year approaches, Rolls-Royce shares are the top holding of a US fund recommended by Warren Buffett. But…

Read more »

Investing Articles

£20k in a high-interest savings account? It could be earning more passive income in stocks

Millions of us want a passive income, but a high-interest savings account might not be the best way to do…

Read more »

Investing Articles

3 tried and tested ways to earn passive income in 2025

Our writer examines the latest market trends and economic forecasts to uncover three great ways to earn passive income in…

Read more »

Investing Articles

Here’s what £10k invested in the FTSE 100 at the start of 2024 would be worth today

Last week's dip gives the wrong impression of the FTSE 100, which has had a pretty solid year once dividends…

Read more »

Investing Articles

UK REITs: a once-in-a-decade passive income opportunity?

As dividend yields hit 10-year highs, Stephen Wright thinks real estate investment trusts could be a great place to consider…

Read more »